苄基氯甲基醚 | 35364-99-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苄基氯甲基醚
• 中文别名: (氯甲氧基甲基)苯
• 英文名称: α-chlorobenzyl methyl ether
• 英文别名: methoxybenzyl chloride；[chloro(methoxy)methyl]benzene
• CAS: 35364-99-9
• 化学式: C₈H₉ClO
• 分子量: 156.612
• InChiKey: YVBSAPDHRXHFHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2909309090

反应信息

• 作为反应物：
  描述：

  苄基氯甲基醚 在 吡啶 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 1,8-dihydroxy-10-(phenylmethylene)-9(10H)-anthracenone
  参考文献：
  名称：

  Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase

  摘要：

  The syntheses, the biological evaluation, and the structure-activity relationships of a novel series of 1,8-dihydroxy-9(10H)-anthracenones bearing acyl-, alkyl-, or alkylidene-linked aromatic substituents in the 10-position are described. The phenylacyl and phenylalkylidene analogs were far more potent inhibitors of 5-lipoxygenase (5-LO) from bovine polymorphonuclear leukocytes (IC50 values in the 10(-7) M range) than the antipsoriatic drug anthralin, whereas phenylalkyl analogs were only weak inhibitors. Among the active compounds were both potent generators of hydroxyl radicals, as determined by deoxyribose degradation, and strong reducers of the stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH). However, several derivatives of this series maintained 5-LO inhibitory activity but did not generate hydroxyl radicals and were not reactive with DPPH. In particular, phenylacyl analogs were also 6 times more efficient in inhibition of lipid peroxidation in model membranes than anthralin. Structure-activity relationships have shown that the presence of free phenolic groups in the attached aromatic ring is beneficial but not required for 5-LO inhibitory potency. The inhibitory potency in the 10-phenylacyl series increased with the length of the acyl chain with three methylene units being the optimum, suggesting a specific enzyme interaction which would not be expected for nonspecific redox inhibitors.

  DOI：

  10.1021/jm00077a015
• 作为产物：
  描述：

  生成 苄基氯甲基醚
  参考文献：
  名称：

  单线卤代苯基碳烯作为强氢键受体

  摘要：

  氯苯卡宾和氟苯卡宾是在低温条件下通过光解相应的基质分离的重氮化合物在水掺杂的氩气基质中生成的。H 2扩散时通过在高于20 K的温度下对基体进行退火来诱导固体氩气中的O，从而在卡宾与水之间形成氢键结合的配合物。这些配合物的紫外线光解导致形成苯甲醛和卤化氢HX。在无定形水冰中重分解二嗪类后，获得相同的产物。显然，在这些条件下，羧甲基苯甲酸酯向H–OH的主要插入产物不稳定，并且苯甲醛通过二次光解形成。在卡宾与甲醇反应中，观察到氯苯基卡宾向O–H键稳定的一级光化学插入产物。

  DOI：

  10.1021/acs.jpca.6b02550
• 作为试剂：
  描述：

  哌啶 、 O-ethyl S-[2-oxo-2-phenylethyl]carbonodithioate 在 苄基氯甲基醚 、 三乙胺 作用下， 生成 1-piperidinecarbothioic acid O-ethyl ester 、 2-(α-methoxybenzylthio)acetophenone
  参考文献：
  名称：

  Brown, Michael D.; Meunier, Catherine J.; Whitham, Gordon H., Journal of the Chemical Society. Perkin transactions I, 1988, p. 813 - 816

  摘要：

  DOI：

文献信息

• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
• [EN] COMPOUNDS THAT INHIBIT MCL-1 PROTEIN<br/>[FR] COMPOSÉS INHIBANT LA PROTÉINE MCL-1
  申请人：AMGEN INC

  公开号：WO2018183418A1

  公开（公告）日：2018-10-04

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (I), or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

  本文提供了髓样细胞白血病1蛋白（Mcl-1）抑制剂，其制备方法，相关的药物组合物，以及使用这些物质的方法。例如，本文提供了化合物的化学式（I）或其立体异构体；以及这些化合物的药用盐和含有这些化合物的药物组合物。本文提供的化合物和组合物可以用于治疗癌症等疾病或症状。
• Depsipeptides and Their Therapeutic Use
  申请人：Shuttleworth Stephen Joseph

  公开号：US20110112090A1

  公开（公告）日：2011-05-12

  A Compound of structure (IX) or (X) or a pharmaceutically acceptable salt thereof, wherein: X is —C(═O)N(R 10 )— or —CH(OPr 3 )—; R 7 , R 9 and R 10 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid; Pr 1 and Pr 2 are the same or different and represent hydrogen or a thiol protecting group; Pr 3 is hydrogen or an alcohol protecting group; R 1 , R 2 , R 5 and R 6 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid, or R 1 and R 2 and/or R 5 and R 6 , taken together with the carbon atom to which they are attached, form a spirocyclic moiety, with the proviso that: each of R 1 and R 2 is not hydrogen, or each of R 5 and R 6 is not hydrogen.

  一种结构化合物（IX）或（X）或其药学上可接受的盐，其中：X为—C(═O)N(R10)—或—CH(OPr3)—；R7、R9和R10相同或不同，代表氢或来自天然或非天然氨基酸的氨基酸侧链基团；Pr1和Pr2相同或不同，代表氢或巯基保护基团；Pr3为氢或醇保护基团；R1、R2、R5和R6相同或不同，代表氢或来自天然或非天然氨基酸的氨基酸侧链基团，或R1和R2和/或R5和R6，与它们连接的碳原子一起形成螺环基团，条件是：R1和R2中的每一个都不是氢，或R5和R6中的每一个都不是氢。
• Substitutions and dehydrogenations by 2,2-bis(trifluoromethyl)-ethylene-1,1-dicarbonitrile via hydride abstraction
  作者：Reinhard Brückner、Rolf Huisgen

  DOI：10.1016/s0040-4039(00)85985-7

  日期：1991.4

  Substitution of benzylic H by the title compound (BTF) gives rise to products with −CH(CF3)2 terminus exclusively; an intermediate benzylic ion pair results from hydride transfer. Instead of ion recombination, proton transfer may be the concluding step generating dehydrogenation products and 2,2-bis(trifluoromethyl)ethane-1,1-dicarbonitrile.

  标题化合物（BTF）取代苄基H生成仅具有-CH（CF 3）2末端的产物；氢化物转移产生中间的苄基离子对。代替离子重组，质子转移可以是产生脱氢产物和2，2-双（三氟甲基）乙烷-1，1-二腈的最后步骤。
• [EN] N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE APPARENTÉS À LA N-ACYLPIPÉRIDINE ÉTHER TROPOMYOSINE
  申请人：PFIZER LTD

  公开号：WO2015092610A1

  公开（公告）日：2015-06-25

  The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.

  本发明涉及本文所述的式(I)化合物及其药学上可接受的盐，以及它们在医学上的用途，特别是作为Trk拮抗剂。